Cost-effectiveness of opportunistic salpingectomy for ovarian cancer prevention.

Data suggesting a link between the fallopian tube and ovarian cancer have led to an increase in rates of salpingectomy at the time of pelvic surgery, a practice known as opportunistic salpingectomy (OS). However, the potential benefits, risks and costs for this new practice are not well established. Our objective was to assess the cost-effectiveness of opportunistic salpingectomy at the time of laparoscopic permanent contraception or hysterectomy for benign indications.
We created two models to compare the cost-effectiveness of salpingectomy versus usual care. The hypothetical study population is 50,000 women aged 45 undergoing laparoscopic hysterectomy with ovarian preservation for benign indications, and 300,000 women aged 35 undergoing laparoscopic permanent contraception. SEER data were used for probabilities of ovarian cancer cases and deaths. The ovarian cancer risk reduction, complication rates, utilities and associated costs were obtained from published literature. Sensitivity analyses and Monte Carlo simulation were performed, and incremental cost-effectiveness ratios (ICERs) were calculated to determine the cost per quality adjusted life year (QALY) gained.
In the laparoscopic hysterectomy cohort, OS is cost saving and would yield $23.9 million in health care dollars saved. In the laparoscopic permanent contraception cohort, OS is cost-effective with an ICER of $31,432/QALY compared to tubal ligation, and remains cost-effective as long as it reduces ovarian cancer risk by 54%. Monte Carlo simulation demonstrated cost-effectiveness with hysterectomy and permanent contraception in 62.3% and 55% of trials, respectively.
Opportunistic salpingectomy for low-risk women undergoing pelvic surgery may be a cost-effective strategy for decreasing ovarian cancer risk at time of hysterectomy or permanent contraception. In our model, salpingectomy was cost-effective with both procedures, but the advantage greater at time of hysterectomy.
AuthorsSarah E Dilley, Laura J Havrilesky, Jamie Bakkum-Gamez, David E Cohn, J Michael Straughn Jr, Aaron B Caughey, Maria I Rodriguez
JournalGynecologic oncology (Gynecol Oncol) Vol. 146 Issue 2 Pg. 373-379 (08 2017) ISSN: 1095-6859 [Electronic] United States
PMID28577884 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
CopyrightCopyright © 2017. Published by Elsevier Inc.
  • Adult
  • Cost-Benefit Analysis
  • Female
  • Humans
  • Hysterectomy (economics, methods)
  • Laparoscopy (economics, methods)
  • Middle Aged
  • Models, Economic
  • Monte Carlo Method
  • Ovarian Neoplasms (economics, prevention & control)
  • Postoperative Complications (economics, epidemiology)
  • Prophylactic Surgical Procedures (economics, methods)
  • Quality-Adjusted Life Years
  • SEER Program
  • Salpingectomy (economics, methods)
  • Sterilization, Tubal (economics, methods)
  • Uterine Diseases (surgery)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!

Choose Username:
Verify Password:
Enter Code Shown: